Stepwise abnormality of sex steroid hormone receptors, tumor suppressor gene products (p53 and Rb), and Cyclin E in Uterine Endometrioid Carcinoma

Cancer

Volumn 77, Issue 2, 1996, Pages 321-329

  Li, Shuan Fang ^a   Shiozawa, Tanri ^a   Nakayama, Kuniaki ^a   Nikaido, Toshio ^a   Fujii, Shingo ^a  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cyclin E; Endometrial carcinoma; p53; Rb; Steroid hormone receptor

Indexed keywords

CYCLIN E; CYCLINE; ESTROGEN; ESTROGEN RECEPTOR; GENE PRODUCT; PROGESTERONE; PROGESTERONE RECEPTOR; PROTEIN P53; RETINOBLASTOMA PROTEIN; SEX HORMONE; STEROID RECEPTOR;

ARTICLE; CONTROLLED STUDY; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

ADULT; AGED; CARCINOMA, ENDOMETRIOID; CYCLINS; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MENOPAUSE; MIDDLE AGED; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RECEPTORS, STEROID; RETINOBLASTOMA PROTEIN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0030028264     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19960115)77:2<321::AID-CNCR15>3.0.CO;2-3     Document Type: Article

References (48)

1. Finlay CA, Hinds PW, Levine AJ. The p53 proto-oncogene can act as a suppressor of transformation. Cell 1989; 57:1083-93.
2. Chen PL, Chen YM, Bookstein R, Lee WH. Genetic mechanisms of tumor suppression by human p53 gene. Science 1990;250:1576-80.
3. Yin Y, Tainsky MA, Bischoff FZ, Strong LC, Wahl GW. Wildtype p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell 1992;70:937-48.
4. Vogelstein B, Kinzler KW. p53 function and dysfunction. Cell 1992;70:523-6.
5. Hollstein M, Sidransky D, Vogelstein B, Harris C. p53 mutations in human cancers. Science 1991;253:49-53.
6. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, et al. Mutations in the p53 gene occur in diverse human tumor types. Nature 1989;342:705-8.
7. Lee WH, Bookstein R, Hong F, Young LJ, Shew JY, Lee EH. Human retinoblastoma susceptibility gene: cloning, identification and sequence. Science 1987;235:1394-9.
8. Fung YK, Murphree AL, T'Ang A, Qian J, Hinrichs SH, Fenedict W. Structural evidence for the authenticity of the human retinoblastoma gene. Science 1987;236:1657-61.
9. Friend SH, Horowitz JM, Gerber MR, Wang XF, Bogenmann E, Li FP, et al. Deletions of a DNA sequence in retinoblastomas and mesenchymal tumors: organization of the sequence and its encoded protein. Proc Natl Acad Sci USA 1987;84:9059-63.
10. Lee EP, To H, Shew JY, Bookstein R, Scully P, Lee WH. Inactivation of the retinoblastoma susceptibility gene in human breast cancers. Science 1988;41:218-21.
11. Harbour JW, Lai SL, Whang-Peng J, Gazdar AF, Minna JD, Kaye FJ. Abnormalities in structure and expression of the human retinoblastoma gene in SCLC. Science 1988;241: 353-7.
12. Sasano H, Comerford J, Silverberg SD, Carrett CT. An analysis of abnormalities of the retinoblastoma gene in human ovarian and endometrial carcinoma. Cancer 1990;66:2150-4.
13. Ali AA, Marcus JN, Harvey JP, Roll R, Hodgson CP, Widrick DM, et al. RB1 protein in normal and malignant human colorectal tissue and colon cancer cell lines. FASEB J 1993;7:931-7.
14. White E. p53, guardian of Rb. Nature 1994;371:21-2.
15. Reich NC, Levine AJ. Growth regulation of a cellular tumor antigen, p53, in nontransformed cells. Nature 1984;308:199-201.
16. Hinds PW, Mittnacht S, Dulic V, Reed SI, Winberg RA. Regulation of retinoblastoma protein functions by ectopic expression of human cyclins. Cell 1992;70:993-1006.
17. Kato J, Matsushime H, Hiebert SW, Ewen ME, Sherr CJ. Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRB phosphorylation by the cyclin D-dependent kinase CDK4. Genes Dev 1993;7:331-42.
18. Keyomarsi K, Pardee AB. Redundant cyclin overexpression and gene amplification in breast cancer cells. Proc Natl Acad Sci USA 1993;90:1112-6.
19. Leach SF, Elledge SJ, Sherr CJ, Willpson JKV, Markowitz S, Kinzler KW, et al. Amplification of cyclin genes in colorectal carcinomas. Cancer Res 1993;53:1986-9.
20. Jiang W, Kahn SM, Tomita N, Zhang YJ, Lu SH, Weinstein B. Amplification and expression of the human cyclin D gene in esophageal cancer. Cancer Res 1992;52:2980-3.
21. Keyomarsi K, O'Leary N, Molnar G, Lees E, Fingert H, Pardee AB. Cyclin E, a potential prognostic marker for breast cancer. Cancer Res 1994;54:380-5.
22. Friberg LG, Noren H. Prognostic value of steroid hormone receptors for 5-year survival in stage II endometrial cancer. Cancer 1993;71:3570-4.
23. Creasman WT. Prognostic significance of hormone receptors in endometrial cancer. Cancer 1993;71:1467-70.
24. Bur ME, Perlman C, Edelmann L, Fey E, Rose PG. p53 expression in neoplasms of the uterine corpus. Am J Clin Pathol 1992;98:81-7.
25. Risinger JI, Dent GA, Ingar-Trowbridge D, Mclachlen JA, Tsao MS, Stentman M, et al. p53 mutations in human endometrial carcinoma. Mol Carcinog 1992;5:250-3.
26. Jiko K, Sasano H, Ito K, Ozawa N, Sato S, Yajima A. Immunohistochemical and in situ hybridization analysis of p53 in human endometrial carcinoma of the uterus. Anticancer Res 1993;13:305-10.
27. Kohler MF, Berchuck A, Davidoff AM, Humphrey PA, Dodge RK, Iglehart JD, et al. Overexpression and mutation of p53 in endometrial carcinoma. Cancer Res 1992;52:1622-7.
28. Ambros RA, Vigna PA, Figge J, Kallakury BVS, Mastrangelo A, Eastman AY, et al. Observation on tumor and metastatic suppressor gene status in endometrial carcinoma with particular emphasis on p53. Cancer 1994;731:1686-92.
29. Enomoto T, Fujita M, Inoue M, Nakazawa-Miyamoto A, Tanizawa O, Nomura T. Alterations of the Rb gene and its association with Ki-ras activation and p53 inactivation in endometrial adenocarcinoma. Mol Carcinog 1993;8:132-7.
30. Enomoto T, Fujita M, Inoue M, Rice JM, Nakajima R, Tanizawa O, et al. Alterations of the p53 tumor suppressor gene and its association with activation of the c-K-ras-2 protooncogene in premalignant and malignant lesions of the human uterine endometrium. Cancer Res 1993;53:1883-8.
31. Kurman RJ, Zaino RJ, Noris HJ. Endometrial carcinoma. In: Kurman RJ, editor. Blaustein's pathology of the female genital tract. 4th edition. New York: Springer-Verlag, 1994:439-86.
32. Lessey BA, Killam AP, Metzger DA, Haney AF, Greene GL, McCarty KS. Immunohistochemical analysis of human uterine estrogen and progesterone receptors throughout the menstrual cycle. J Clin Endocrinol Metab 1988;67:334-40.
33. Press MF, Greene GL. Localization of progesterone receptor with monoclonal antibody to the human progestin receptor. Endocrinology 1988;122:1165-75.
34. Press MF, Nousek-Goebl NA, Bur M, Greene GL. Immunohistochemical assessment of estrogen receptor distribution in the human endometrium throughout the menstrual cycle. Lab Invest 1984;51:495-503.
35. Masuzawa H, Badokhon NH, Nakayama K, Konishi I, Nikaido T, Fujii S. Failure of down-regulation of estrogen receptors and progesterone receptors after medroxyprogesterone acetate administration for endometrial hyperplasias. Cancer 1994;474:2321-8.
36. Nyholm HCJ, Nielsen AL, Lynrup J, Norup P, Thorpe SM. Biochemical and immunohistochemical estrogen and progesterone receptors in adenomatous hyperplasia and endometrial carcinoma; correlation with stage and other clinicopathological features. Am J Obstet Gynecol 1992;167:1334-42.
37. Bergeron C, Ferenczy A, Shyamala G. Distribution of estrogen receptors in various cell types of normal, hyperplastic, and neoplastic human endometrial tissues. Lab Invest 1988;58:338-45.
38. Bergeron C, Ferenczy A, Toft DO, Shyamala G. Immunocytochemical study of progesterone receptors in hyperplastic and neoplastic human endometrial tissues. Cancer Res 1988;48:6132-6.
39. Wang D, Konishi I, Koshiyama M, Mandai M, Nanbu Y, Ishikawa Y, et al. Expression of c-erbB2 protein and epithelial growth factor receptor in endometrial carcinomas. Correlation with clinical pathologic and sex steroid receptor status. Cancer 1993;72:2628-37.
40. Bodner SM, Minna JD, Jensen SM, D'Amico D, Carbone D, Mitsudomi T, et al. Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation. Oncogene 1992;7:743-9.
41. Kupryjanczyk J, Thor AD, Beauchamp R, Merritt V, Edgerton SM, Bell DA, et al. p53 gene mutations and protein accumulation in human ovarian cancer. Proc Natl Acad Sci USA 1993;90:4961-5.
42. Teneriello MG, Ebina M, Linnoila RI, Henry M, Nash JD, Park RC, et al. p53 and Ki-ras gene mutations in epithelial ovarian neoplasms. Cancer Res 1993;53:1-6.
43. Koshiyama M, Konishi I, Wang DP, Mandai M, Komatsu T, Yamamoto S, et al. Immunohistochemical analysis of p53 protein over-expression in endometrial carcinomas: inverse correlation with sex steroid receptor status. Virchows Arch A Pathol Anat Histoparhol 1993;423:265-71.
44. Ito K, Watanabe K, Nasim S, Sasano H, Sato S, Yajima A, et al. Prognostic significance of p53 overexpression in endometrial cancer. Cancer Res 1994;54:4667-70.
45. Baker SJ, Preisinger AC, Jessup JM, Paraskeva C, Makowitz S, Willson JK. p53 gene mutations occur in combination with 17p alleic deletions as late events in colorectal tumorigenesis. Cancer Res 1990;50:7717-22.
46. Cattoretti G, Rilke F, Andreola S, D'Amato L, Delia D. p53 expression in breast cancer. Int J Cancer 1988;41:178-83.
47. Lu X, Park SH, Thompson TC, Lane DP. ras-induced hyperplasia occurs with mutation of p53, but activated ras and myc together can induce carcinoma without p53 mutation. Cell 1992;70:153-61.
48. Duggan BD, Felix JC, Muderspach LI, Tsao J, Shibata DK. Early mutational activation of the c-ki-ras oncogene in endometrial carcinoma. Cancer Res 1994;54:1604-7.